Diabetic retinopathy is an eye condition that causes ... Anti-VEGF drugs include aflibercept (Eylea), bevacizumab (Avastin), and ranibizumab (Lucentis). Focal/grid macular laser surgery.

Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

investigators excluded diagnoses that would fall within FDA-approved anti-VEGF indications or bevacizumab-vikg indications ...

and the Diabetic Retinopathy Clinical Research Network, and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label ...

For bevacizumab only two clinical trials have ... Active untreated proliferative diabetic retinopathy in the study eye. Any intraocular surgery in the study eye within 3 months prior to randomization.

In diabetic retinopathy, high blood sugar levels damage blood vessels in the retina, which can lead to retinal cell death due to an inadequate supply of oxygen.Treatments for the condition include ...

"We have great treatments for diabetic retinopathy," Cai explained in an online blog. "However, it is important to get regular eye examinations so that your doctor can offer you these treatments ...

which in turn leads to faster progression of diabetic retinopathy. Diabetic retinopathy (DR) is an eye condition that can ...

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...